Changchun BCHT Biotechnology Co. Share Price

Equities

688276

CNE100005XY6

Pharmaceuticals

End-of-day quote Shanghai S.E. 23:00:00 11/07/2024 BST 5-day change 1st Jan Change
31.07 CNY -1.37% Intraday chart for Changchun BCHT Biotechnology Co. -0.22% -43.31%

Financials

Sales 2024 * 2.47B 341M 26.29B Sales 2025 * 3.02B 417M 32.13B Capitalization 12.85B 1.77B 137B
Net income 2024 * 710M 97.94M 7.54B Net income 2025 * 931M 128M 9.89B EV / Sales 2024 * 5.19 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 4.25 x
P/E ratio 2024 *
18.2 x
P/E ratio 2025 *
13.8 x
Employees 1,241
Yield 2024 *
0.99%
Yield 2025 *
1.3%
Free-Float 21.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.37%
1 week-0.22%
Current month+9.52%
1 month-2.30%
3 months-23.38%
6 months-41.50%
Current year-43.31%
More quotes
1 week
29.02
Extreme 29.02
31.82
1 month
28.20
Extreme 28.2
32.11
Current year
28.20
Extreme 28.2
58.50
1 year
28.20
Extreme 28.2
68.50
3 years
28.20
Extreme 28.2
109.80
5 years
28.20
Extreme 28.2
135.88
10 years
28.20
Extreme 28.2
135.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 31/12/03
Director of Finance/CFO 60 31/01/19
Chairman 58 29/02/04
Members of the board TitleAgeSince
Director/Board Member 55 29/02/04
Director/Board Member 57 02/08/21
Director/Board Member 60 20/02/19
More insiders
Date Price Change Volume
12/07/24 31.07 -1.37% 3,074,238
11/07/24 31.5 +3.14% 5,102,630
10/07/24 30.54 +2.11% 4,233,078
09/07/24 29.91 -0.63% 4,483,915
08/07/24 30.1 -3.34% 5,250,346

End-of-day quote Shanghai S.E., July 11, 2024

More quotes
Changchun BCHT Biotechnology Co is a China-based innovative biomedical company mainly dedicated to the prevention and treatment of infectious diseases. The Company is mainly engaged in the research and development, production and sales of human vaccines. The Company has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The Company also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The Company mainly conducts business within the domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
31.07 CNY
Average target price
54.56 CNY
Spread / Average Target
+75.62%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688276 Stock